Article first published online: 17 JAN 2013
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 57, Issue 5, pages 1752–1762, May 2013
How to Cite
Everson, G. T., Terrault, N. A., Lok, A. S., Rodrigo, D. R., Brown, R. S., Saab, S., Shiffman, M. L., Al-Osaimi, A. M.S., Kulik, L. M., Gillespie, B. W., Everhart, J. E. and and the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (2013), A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology, 57: 1752–1762. doi: 10.1002/hep.25976
Potential conflict of interest: Dr. Everson advises, consults for, and received grants from Merck and Schering-Plough. Dr. Terrault consults for, and received grants from Roche and Genentech. Dr. Lok consults for and received grants from Schering-Plough, Merck, Roche, and Genentech. Dr. Brown consults for Merck. Dr. Saab owns stock in, consults for, advises, and is in the speakers' bureau of Bristol-Myers Squibb. He consults for, advises, and is on the speakers' bureau of Genentech and Merck. Dr. Al-Osaimi consults for, advises, is on the speakers' bureau of, and received grants from Merck and Vertex. He is on the speakers' bureau of and received grants from Idenix, Novartis, and Gilead. He also consults for Amgen and received grants from Genentech, Valeant, Intermune, Pharmasset, HemoLife Medical, Genzyme, Ortho Biotech, GalxoSMithKline, Sanofi-Aventis, Bayer Healthcare, Hyperion, Bristol-Myers Squibb, Vital, and Octapharma. Dr. Shiffman advises and received grants from Achillion, Boehringer-Ingelheim, Globeimmune, Inhibitex, Novartis, Vertex, and Zymogenetics. He consults for Biolex, Human Genome Sciences, Romark. He advises Pfizer and Janssen. He received grants from Idenix. He advises, is on the speakers' bureau of, and received grants from Schering-Plough, Gilead, and Bristol-Myers Squibb. He consults for, advises, and received grants from Conatus. He consults for, advises, is on the speakers bureau of, and received grants from Roche and Anandys. He is on the speakers' bureau of and advises Bayer.
The results of this study were presented, in part, at the 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 30-November 1, 2009.
The study is registered in ClinicalTrials.gov (no. NCT00135798).
This is publication 18 of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study.
- Issue published online: 22 APR 2013
- Article first published online: 17 JAN 2013
- Accepted manuscript online: 23 JUL 2012 06:09AM EST
- Manuscript Accepted: 11 JUN 2012
- Manuscript Received: 8 MAR 2012
Hepatitis C virus (HCV) infection recurs in liver recipients who are viremic at transplantation. We conducted a randomized, controlled trial to test the efficacy and safety of pretransplant pegylated interferon alpha-2b plus ribavirin (Peg-IFN-α2b/RBV) for prevention of post-transplant HCV recurrence. Enrollees had HCV and were listed for liver transplantation, with either potential living donors or Model for End-Stage Liver Disease upgrade for hepatocellular carcinoma. Patients with HCV genotypes (G) 1/4/6 (n = 44/2/1) were randomized 2:1 to treatment (n = 31) or untreated control (n = 16); HCV G2/3 (n=32) were assigned to treatment. Overall, 59 were treated and 20 were not. Peg-IFN-α2b, starting at 0.75 μg/kg/week, and RBV, starting at 600 mg/day, were escalated as tolerated. Patients assigned to treatment versus control had similar baseline characteristics. Combined virologic response (CVR) included pretransplant sustained virologic response and post-transplant virologic response (pTVR), defined as undetectable HCV RNA 12 weeks after end of treatment or transplant, respectively. In intent-to-treat analyses, 12 (19%) assigned to treatment and 1 (6%) assigned to control achieved CVR (P = 0.29); per-protocol values were 13 (22%) and 0 (0%) (P = 0.03). Among treated G1/4/6 patients, 23 of 30 received transplant, of whom 22% had pTVR; among treated G2/3 patients 21 of 29 received transplant, of whom 29% had pTVR. pTVR was 0%, 18%, and 50% in patients treated for <8, 8-16, and >16 weeks, respectively (P = 0.01). Serious adverse events (SAEs) occurred with similar frequency in treated versus untreated patients (68% versus 55%; P = 0.30), but the number of SAEs per patient was higher in the treated group (2.7 versus 1.3; P = 0.003). Conclusion: Pretransplant treatment with Peg-IFN-α2b/RBV prevents post-transplant recurrence of HCV in selected patients. Efficacy is higher with >16 weeks of treatment, but treatment is associated with increased risk of potentially serious complications. (HEPATOLOGY 2013)